Citius Pharmaceuticals logo
Citius Pharmaceuticals CTXR
$ 0.51 4.08%
report update icon

Quarterly report 2026-Q2
added 05-15-2026

Citius Pharmaceuticals Net Debt | CTXR

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Citius Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
-3.44 M -2.99 M -26 M -41 M -69.2 M -13.5 M -7.72 M -9.01 M -3.03 M 379 K -676 K -952 K 3.21 K 16.9 K 18.3 K -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
379 K -69.2 M -11.8 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
TCR2 Therapeutics TCR2 Therapeutics
TCRR
-7.6 M - - $ 58.1 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
-13.8 M - -14.27 % $ 1.7 M singaporeSingapore
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
BELLUS Health BELLUS Health
BLU
-86 M - - $ 2.47 B canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
-290 M - - $ 13.6 B usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
-44.8 M - - $ 29.6 M usaUSA
GeoVax Labs GeoVax Labs
GOVX
-2.82 M $ 1.83 -4.45 % $ 8.35 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
16 M - -33.41 % $ 3.37 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Tyme Technologies Tyme Technologies
TYME
-107 M - 8.07 % $ 54 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
-169 M - - $ 12.2 B usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
295 M - - $ 309 M usaUSA
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
-28 M - -1.38 % $ 46.8 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
-57.9 M - -0.75 % $ 18.7 M danmarkDanmark
9 Meters Biopharma 9 Meters Biopharma
NMTR
-12.5 M - -42.97 % $ 1.05 M usaUSA
Theratechnologies Theratechnologies
THTX
-14.7 M - - $ 83.9 M canadaCanada
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
-36.2 M - -15.15 % $ 60.3 M britainBritain
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
-5.36 M - -60.05 % $ 125 K usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
-39.4 M - -55.98 % $ 2.15 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
-69.2 M - - $ 527 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
223 M - - $ 121 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
-61.1 M - - $ 521 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
-12.2 M $ 34.99 3.77 % $ 147 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
11.2 M - -47.76 % $ 6.27 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
-48.6 M - - - russiaRussia
Kiromic BioPharma Kiromic BioPharma
KRBP
-224 K - 6.61 % $ 3.08 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
-57.6 M - - $ 2.18 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
-22.5 M - - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
-15.9 M - 0.42 % $ 213 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-3.05 M - 17.91 % $ 11.1 M usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
-2.75 M - -3.76 % $ 3.47 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
-38.8 M - -6.92 % $ 79.4 M usaUSA
Otonomy Otonomy
OTIC
-58.1 M - -1.96 % $ 4.68 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
-174 M $ 286.96 0.01 % $ 5.55 B usaUSA
Фармсинтез Фармсинтез
LIFE
612 M - - - russiaRussia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
-46.3 M $ 1.04 -4.59 % $ 32.4 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
-6.38 M - -24.12 % $ 1.56 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
-127 M - - $ 401 M usaUSA
Histogen Histogen
HSTO
-11.9 M - 31.6 % $ 2.12 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
-40.8 M - - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
293 M - -7.23 % $ 13 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
-513 M - - $ 1.62 B israelIsrael
Omeros Corporation Omeros Corporation
OMER
84 M $ 13.23 -5.71 % $ 840 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-2.04 M $ 0.94 -10.44 % $ 2.32 B israelIsrael
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
-39.4 M - 7.4 % $ 6.29 M usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
-44.7 M - - $ 958 M usaUSA